

Pipeline and Portfolio Expansion: Late Stage Development¹

BAUSCH + LOMB

| Product | Status / Upcoming Milestone |
|--|--|
| SiHy Daily | Launched in Japan, U.S., Australia, Hong Kong, South Korea, Singapore and Canada; Launching SVS into 30+ countries and multi-focal into 5+ countries |
| Biotrue® Hydration Plus Multi-purpose Solution | National U.S. launch expected summer 2022 |
| LUMIFY® Line Extensions | Phase 3 clinical studies expected to start in 2022 |
| enVista® Modified Monofocal IOL | Expected launch late 2023 |
| enVista® Extended Depth of Focus IOL | Expect 2025 launch |
| enVista® Trifocal (Intraocular Lens) | Canadian study completed enrollment in 1Q22 Enrollment expected to complete 1H22 for U.S. study |
| StableVisc™ Cohesive OVD | Enrollment completed for StableVisc™ in 4Q21; Expect Clinical Study Report 2Q22 |
| XIPERE™ ² (macular edema associated with uveitis) | Launched 1Q22 in U.S. |
| NOV03 ³ (dry eye disease associated with meibomian gland dysfunction) | Announced statistically significant topline data from both Phase 3 studies; Anticipate filing an NDA in 1H22 |
| Biosimilar candidate for Lucentis (ranibizumab) | Xbrane filed aBLA ⁶ with FDA in 1Q22 |
| Microdose formulation of atropine ophthalmic solution (reduction of pediatric myopia progression in children ages 3-12) ⁴ | Expect to complete enrollment for Phase 3 study during 2H22 |
| Myopia control contact lens ⁵ | Myopia control contact lens design ⁵ licensed from BHVI |
| eyeTELLIGENCE™ clinical decision support software | Entered into an agreement with Lochan LLC to develop the next generation of eyeTELLIGENCE™ clinical decision support software in June 2021 |

1. See slide 1 of BHC 1Q 2022 earnings presentation for further information on forward-looking statements.

2. Exclusive licensing agreement with Clearside Biomedical, Inc.

3. In 2019, the Company acquired an exclusive license from Novalliq GmbH for the commercialization and development of NOV03 in the United States and Canada.

4. Exclusive licensing agreement with EyeNovia, Inc.

5. Exclusive licensing agreement with BHVI.

6. Abbreviated biologics license application.